AMS vs SILO
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AMS exhibits severe financial distress, anchored by a weak Piotroski F-Score of 2/9 and a critical liquidity position with a current ratio of 0.76. The company is experiencing a systemic decline, evidenced by a -14.80% YoY revenue contraction and a disastrous -200% YoY EPS growth. Despite a low Price-to-Book ratio of 0.37, the stock is in a technical freefall (0/100 trend) and consistently misses earnings estimates by wide margins. The combination of negative profitability and shrinking top-line growth suggests a value trap rather than a value opportunity.
SILO exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total lack of fundamental improvement across all measured categories. The company is currently pre-revenue or stagnant (0% YoY growth) with an unsustainable operating margin of -4363.27%. While a high current ratio of 11.36 suggests a temporary cash runway, the long-term trajectory is severely negative with a 5-year price decline of 96%. The recent 1-month price spike appears to be speculative volatility rather than a fundamental turnaround.
Compare Another Pair
Related Comparisons
AMS vs SILO: Head-to-Head Comparison
This page compares American Shared Hospital Services (AMS) and Silo Pharma, Inc. (SILO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.